Granules receives 4 USFDA observations for US facility

Granules receives 4 USFDA observations for US facility. The USFDA raised four Form-483 observations following an inspection of Granules’ manufacturing plant in the US. These observations highlight compliance issues that may impact drug approvals and exports. Granules must respond with corrective actions to avoid regulatory escalation.

📊 STOCKS: GRANULES | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #USFDA